Hartmut Goldschmidt

Hartmut Goldschmidt

UNVERIFIED PROFILE

Are you Hartmut Goldschmidt?   Register this Author

Register author
Hartmut Goldschmidt

Hartmut Goldschmidt

Publications by authors named "Hartmut Goldschmidt"

Are you Hartmut Goldschmidt?   Register this Author

100Publications

2274Reads

20Profile Views

[Current Recommendations for the First-Line Therapy of Symptomatic Multiple Myeloma].

Dtsch Med Wochenschr 2020 Jun 17;145(12):813-819. Epub 2020 Jun 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1009-5756DOI Listing
June 2020

Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.

Eur J Haematol 2020 May 22;104(5):443-458. Epub 2020 Feb 22.

Department of Clinical Therapeutics, Hematology & Medical Oncology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13379DOI Listing
May 2020

Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma.

Biol Blood Marrow Transplant 2020 May 16. Epub 2020 May 16.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.04.030DOI Listing
May 2020

Can F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

Cancers (Basel) 2020 May 23;12(5). Epub 2020 May 23.

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051335DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281312PMC
May 2020

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.

Leuk Lymphoma 2020 01 19;61(1):27-36. Epub 2019 Aug 19.

Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1646905DOI Listing
January 2020

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.

Qual Life Res 2020 Jan 24;29(1):69-79. Epub 2019 Sep 24.

Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-019-02307-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962286PMC
January 2020

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.

Molecules 2019 Dec 29;25(1). Epub 2019 Dec 29.

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules25010134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982887PMC
December 2019

Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRI.

Diagnostics (Basel) 2019 Nov 7;9(4). Epub 2019 Nov 7.

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics9040179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963877PMC
November 2019

Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example.

Clin Lymphoma Myeloma Leuk 2019 10 4;19(10):635-644.e2. Epub 2019 Jul 4.

Department of Hematology, Oncology, and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany; Department of Hematology and Oncology, National Center of Tumor Diseases, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.06.012DOI Listing
October 2019

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Authors:
Amand F Schmidt Michael V Holmes David Preiss Daniel I Swerdlow Spiros Denaxas Ghazaleh Fatemifar Rupert Faraway Chris Finan Dennis Valentine Zammy Fairhurst-Hunter Fernando Pires Hartwig Bernardo Lessa Horta Elina Hypponen Christine Power Max Moldovan Erik van Iperen Kees Hovingh Ilja Demuth Kristina Norman Elisabeth Steinhagen-Thiessen Juri Demuth Lars Bertram Christina M Lill Stefan Coassin Johann Willeit Stefan Kiechl Karin Willeit Dan Mason John Wright Richard Morris Goya Wanamethee Peter Whincup Yoav Ben-Shlomo Stela McLachlan Jackie F Price Mika Kivimaki Catherine Welch Adelaida Sanchez-Galvez Pedro Marques-Vidal Andrew Nicolaides Andrie G Panayiotou N Charlotte Onland-Moret Yvonne T van der Schouw Giuseppe Matullo Giovanni Fiorito Simonetta Guarrera Carlotta Sacerdote Nicholas J Wareham Claudia Langenberg Robert A Scott Jian'an Luan Martin Bobak Sofia Malyutina Andrzej Pająk Ruzena Kubinova Abdonas Tamosiunas Hynek Pikhart Niels Grarup Oluf Pedersen Torben Hansen Allan Linneberg Tine Jess Jackie Cooper Steve E Humphries Murray Brilliant Terrie Kitchner Hakon Hakonarson David S Carrell Catherine A McCarty Kirchner H Lester Eric B Larson David R Crosslin Mariza de Andrade Dan M Roden Joshua C Denny Cara Carty Stephen Hancock John Attia Elizabeth Holliday Rodney Scott Peter Schofield Martin O'Donnell Salim Yusuf Michael Chong Guillaume Pare Pim van der Harst M Abdullah Said Ruben N Eppinga Niek Verweij Harold Snieder Tim Christen D O Mook-Kanamori Stefan Gustafsson Lars Lind Erik Ingelsson Raha Pazoki Oscar Franco Albert Hofman Andre Uitterlinden Abbas Dehghan Alexander Teumer Sebastian Baumeister Marcus Dörr Markus M Lerch Uwe Völker Henry Völzke Joey Ward Jill P Pell Tom Meade Ingrid E Christophersen Anke H Maitland-van der Zee Ekaterina V Baranova Robin Young Ian Ford Archie Campbell Sandosh Padmanabhan Michiel L Bots Diederick E Grobbee Philippe Froguel Dorothée Thuillier Ronan Roussel Amélie Bonnefond Bertrand Cariou Melissa Smart Yanchun Bao Meena Kumari Anubha Mahajan Jemma C Hopewell Sudha Seshadri Caroline Dale Rui Providencia E Costa Paul M Ridker Daniel I Chasman Alex P Reiner Marylyn D Ritchie Leslie A Lange Alex J Cornish Sara E Dobbins Kari Hemminki Ben Kinnersley Marc Sanson Karim Labreche Matthias Simon Melissa Bondy Philip Law Helen Speedy James Allan Ni Li Molly Went Niels Weinhold Gareth Morgan Pieter Sonneveld Björn Nilsson Hartmut Goldschmidt Amit Sud Andreas Engert Markus Hansson Harry Hemingway Folkert W Asselbergs Riyaz S Patel Brendan J Keating Naveed Sattar Richard Houlston Juan P Casas Aroon D Hingorani

BMC Cardiovasc Disord 2019 10 29;19(1):240. Epub 2019 Oct 29.

Institute of Cardiovascular Science, University College London, 222 Euston Road, London, NW1 2DA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12872-019-1187-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820948PMC
October 2019

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Clin Lymphoma Myeloma Leuk 2019 08 2;19(8):522-530.e1. Epub 2019 May 2.

Department of Clinical Therapeutics, University Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.04.018DOI Listing
August 2019

Do we need cytogenetics in the follow-up of multiple myeloma?

Br J Haematol 2019 05 1;185(3):399-401. Epub 2019 Feb 1.

Section Multiple Myeloma, Department Haematology, Oncology and Rheumatology, University Hospital Heidelberg and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15781DOI Listing
May 2019

Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Front Genet 2019 8;10:424. Epub 2019 May 8.

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2019.00424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518313PMC
May 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Ann Hematol 2019 Jan 23;98(1):1-18. Epub 2018 Nov 23.

INSERM, UMR_S 938, Proliferation and Differentiation of Stem Cells, Paris, 75012, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3546-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334731PMC
January 2019

Cell-based immunotherapy approaches for multiple myeloma.

Br J Cancer 2019 01 6;120(1):38-44. Epub 2018 Dec 6.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0346-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325139PMC
January 2019

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Nat Commun 2019 01 10;10(1):213. Epub 2019 Jan 10.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08107-8
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08107-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328616PMC
January 2019

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Leukemia 2018 12 6;32(12):2717-2719. Epub 2018 Jul 6.

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0202-1DOI Listing
December 2018

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Leuk Lymphoma 2018 11 4;59(11):2660-2669. Epub 2018 Apr 4.

a Department of Internal Medicine V , University Hospital Heidelberg , Heidelberg , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1443450DOI Listing
November 2018

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Nat Commun 2018 09 13;9(1):3707. Epub 2018 Sep 13.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-04989-w
Publisher Site
http://dx.doi.org/10.1038/s41467-018-04989-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137048PMC
September 2018

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.

BMC Cancer 2018 Aug 15;18(1):820. Epub 2018 Aug 15.

Division of Molecular Genetic Epidemiology, German cancer research center (DKFZ), Im Neuenheimer Feld 580, DE-69120, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4728-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094450PMC
August 2018

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

Crit Rev Oncol Hematol 2018 Jun 29;126:19-23. Epub 2018 Mar 29.

Department of Internal Medicine V, University Hospital Heidelberg, and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.03.021DOI Listing
June 2018

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Haematologica 2018 04 1;103(4):e162-e164. Epub 2018 Feb 1.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.184226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865437PMC
April 2018

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 17;36(8):728-734. Epub 2018 Jan 17.

David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain; Mihaela Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo Clinic, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5032DOI Listing
March 2018

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Hematol Oncol 2018 Feb 25;36(1):258-261. Epub 2017 Aug 25.

Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2473
Publisher Site
http://dx.doi.org/10.1002/hon.2473DOI Listing
February 2018

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Blood Cancer J 2018 02 15;8(2):22. Epub 2018 Feb 15.

Department of Pathology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, 52242, Iowa, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0060-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814454PMC
February 2018

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Transfus Med Hemother 2018 Jan 4;45(1):24-31. Epub 2017 Oct 4.

Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hesse, Mannheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000478911DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836245PMC
January 2018

Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.

Biol Blood Marrow Transplant 2017 Nov 25;23(11):1870-1878. Epub 2017 Jul 25.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Germany; Amyloidosis Center, Heidelberg University, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.07.015DOI Listing
November 2017

Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Am J Nucl Med Mol Imaging 2017 1;7(4):148-156. Epub 2017 Sep 1.

Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ)Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596317PMC
September 2017